SCHEMBL1178671

SCHEMBL1178671

Cc1cc(-c2nc(-c3cc(C)nc(CCCN)n3)no2)cc(C)n1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TP53 P04637 3/20 0.35
PKM P14618 3/20 0.35
S1PR1 P21453 6/20 0.34
NPC1 O15118 6/20 0.34
RAB9A P51151 5/20 0.34
GAA P10253 1/20 0.34
S1PR5 Q9H228 1/20 0.34
MAPT P10636 3/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1178757 0.90 NPC1 (0.33) TP53S1PR1NPC1RAB9AGAA
SCHEMBL1180025 0.85 GRM5 (0.32) GRM5MEN1KMT2ATP53PKM
SCHEMBL1179884 0.81 NPC1 (0.35) MEN1KMT2ATP53S1PR1NPC1
SCHEMBL1179095 0.81 S1PR1 (0.37) S1PR1NPC1RAB9AALDH1A1
SCHEMBL1179249 0.79 S1PR1 (0.34) S1PR1NPC1RAB9AMAPTALDH1A1
SCHEMBL1179057 0.73 S1PR1 (0.34) GRM5MEN1KMT2ATP53PKM
SCHEMBL1178943 0.71 S1PR1 (0.35) TP53S1PR1NPC1RAB9AMAPT
SCHEMBL1179422 0.70 GRM5 (0.39) GRM5MEN1KMT2ATP53PKM
SCHEMBL1180309 0.69 S1PR1 (0.40) GRM5MEN1KMT2ATP53PKM
SCHEMBL3409326 0.68 GRM5 (0.33) GRM5MEN1KMT2ATP53PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US claimed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP claimed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO claimed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 GRM5 1872/4885MEN1 4570/4885KMT2A 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.